Bal Pharma Ltd 16 Nov 2026 12:00 AM
Bal Pharma Ltd consolidated sales up 1.50% on year in Q2FY2027, net profit jumped 25.44%,
Bal Pharma Ltd`s net profit surged by 25.44% to Rs 1.43 crore, while revenue from operations slightly gained 1.50% to Rs 89.95 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.76 lakh crore, rising 6.98%. It has softened by 0.66% over last one week and ticked higher by 6.26% in last one month while the market capitalization of Bal Pharma Ltd has marginally improved by 8.02% and 5.26% in the same period respectively. Profit before tax (PBT) of Bal Pharma Ltd stood at Rs 1.93 crore in Q2 FY27, jumping 168.06% year-on-year, and rallying 69.30% quarter-on-quarter. EBITDA came in at Rs 7 crore, surging by 52.49% YoY and declining 6.39% sequentially. Total expenses grew marginally by 1.45% to Rs 84.66 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 50.83 crore, inching up 4.87% YoY, while employee benefits expense was at Rs 18.18 crore, easing 6.57% YoY. For FY26, revenue from operations posted a slight growth of 2.83% to Rs 311.66 crore, while net profit dropped 12.71% to Rs 6.32 crore, compared to previous FY. EBITDA witnessed a strong improvement of 2767% to Rs 29.97 crore, and PBT improved 15.37% to Rs 5.93 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 30.84 crore in FY26, as against Rs 20.32 crore in FY25. Bal Pharma Ltd soared by 12.84% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.
Bal Pharma Ltd 12 Nov 2026 12:00 AM
Bal Pharma Ltd consolidated sales up 1.50% on year in Q2FY2027, net profit jumped 25.44%,
Bal Pharma Ltd share price inched up 0.74% to Rs 84.03 after the company`s net profit saw a strong growth of 25.44% to Rs 1.43 crore, while revenue from operations improved marginally 1.50% to Rs 89.95 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, easing 5.82%. It has marginally improved by 3.49% over last one week and ticked higher by 6.26% in last one month while the market capitalization of Bal Pharma Ltd has improved by 2.73% and 2.92% in the same period respectively. Profit before tax (PBT) of Bal Pharma Ltd stood at Rs 1.93 crore in Q2 FY27, rallying 168.06% year-on-year, and surging by 69.30% quarter-on-quarter. EBITDA came in at Rs 7 crore, expanding by 52.49% YoY and declining 6.39% sequentially. Total expenses posted a minor rise of 1.45% to Rs 84.66 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 50.83 crore, inching up 4.87% YoY, while employee benefits expense was at Rs 18.18 crore, ticking higher by 6.57% YoY. For FY26, revenue from operations posted a slight growth of 2.83% to Rs 311.66 crore, while net profit dropped 12.71% to Rs 6.32 crore, compared to previous FY. EBITDA soared by 2767% to Rs 29.97 crore, and PBT rose 15.37% to Rs 5.93 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 30.84 crore in FY26, as against Rs 20.32 crore in FY25. Bal Pharma Ltd ticked higher by 4.71% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.37% during the same period.
Bal Pharma Ltd 03 Nov 2026 12:00 AM
Bal Pharma Limited’s board will convene November 11 to review financial results,
Bal Pharma Limited will hold a board meeting on Wednesday, November 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Bal Pharma Ltd 13 Oct 2026 12:00 AM
Bal Pharma disbursed a Rs 1.20 per share dividend following its annual meeting,
Bal Pharma Limited announced that it has disbursed a final dividend of Rs 1.20 per equity share of Rs 10 each for the financial year 2025–26, following approval at its 39th Annual General Meeting on September 24, 2026. The company withheld dividend payments for shareholders with incomplete KYC details or invalid bank accounts, and those amounts will be transferred to the Company’s Unpaid Dividend Account after 30 days, in accordance with the Companies Act, 2013. Shareholders are advised to update their KYC and bank account details with MUFG Intime India Private Limited, the company’s Registrar and Transfer Agent, to facilitate the release of withheld dividends.
Bal Pharma Ltd 07 Oct 2026 12:00 AM
Bal Pharma reported securities dematerialization details to Indian stock exchanges,
Bal Pharma Limited informed the National Stock Exchange of India Limited and BSE Limited that, based on a certificate received from its Registrar and Transfer Agent, MUFG Intime India Private Limited, the details of securities dematerialised/rematerialised during the quarter ended September 30, 2026, have been duly furnished to both stock exchanges within the prescribed time limit.
Subscribe for our
newsletter
Open Account Now